Medpage Today on MSN9d
Dupilumab Improves Quality of Life for COPD Patients
Patients with chronic obstructive pulmonary disease (COPD) and type 2 inflammation had greater improvements in quality of ...
Medscape2d
Children With Severe AD Catch Up on Growth With Dupilumab
Effective treatment with dupilumab may allow younger children with severe atopic dermatitis and short stature to catch up on ...
Medscape9d
Late Dupilumab Responders Have Unique Molecular Profile
In a major potential step toward personalized therapy for atopic dermatitis, data suggest early, late, and no clinical ...
HealthDay on MSN11d
CHEST: Dupilumab for COPD Tied to Improvement in Health-Related Quality of Life
Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and ...
Too Old to Operate7d
Long-Term Clinical Effectiveness of Dupilumab in Patients With COPD
The following is a summary of “Clinical Effectiveness and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease ...
Business Insider22d
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab ...
emjreviews.com16d
Dupilumab Offers Benefits in Bullous Pemphigoid Management
New trial results show dupilumab significantly improves remission rates and reduces symptoms in patients with bullous ...
Daily4d
Dupilumab therapy reduced atopic dermatitis symptoms in pediatric population, finds study
A new study published in the Journal of American Academy of Dermatology found that Dupilumab improved atopic dermatitis (AD) ...
Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space
The separation of Ebglyss from Dupixent and Adbry/Adtralza will depend on real-world clinical benefits, patient experience ...
Dupilumab for COPD tied to improvement in health-related quality of life
Dupilumab improves health-related quality of life (HRQoL) in patients with chronic obstructive pulmonary disease (COPD) and ...
Nasdaq21d
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven in part by type 2 inflammation or other allergic processes in ...